Notably, shC tumor-bearing mice treated with MitoX in conjunction with TPX, compared with mice subjected to TPX or MitoX monotherapy, showed dramatic tumor growth inhibition (p = 0.003 for MitoX + TPX v.s. TPX; p < 0.001 for MitoX + TPX v.s. MitoX; Figure 5A). Here, TPO is linked to neoplasm.